Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune Hepatitis
- 241 Downloads
Acute onset autoimmune hepatitis (AIH) shows acute presentation like acute hepatitis and does not have typical clinicopathological features of AIH. There is no gold standard for making the diagnosis. Therefore, losing the timing of starting immunosuppressive therapy, some of the cases develop into severe or fulminant form and have poor prognosis.
Our aim was to elucidate the efficacy of intravenous glycyrrhizin in decreasing alanine aminotransferase (ALT) level in the early stage of acute onset AIH.
Thirty-one patients were defined as acute onset AIH based on our uniform criteria, and were enrolled in this study. We prospectively treated 17 patients with sufficient doses (100 ml/day) of intravenous glycyrrhizin (SNMC) at an early stage (SNMC group), and treated 14 patients of severe disease with intravenous glycyrrhizin and corticosteroids (CS) (SNMC + CS group). We examined their clinical and biochemical features and treatment responses.
The ALT level could be controlled at an early stage using SNMC with no significant difference compared with SNMC + CS, and responsiveness to the therapy was determined by the disease severity at the time of starting therapy rather than the time duration from onset to therapy. Recovery rate was higher in the SNMC group than in the SNMC + CS group (P = 0.035).
The early introduction of sufficient doses of SNMC might prevent disease progression in patients with acute onset AIH. SNMC can be used safely and be useful for patients with difficult-to-diagnose acute liver disease as an ‘initial’ treatment tool to improve liver inflammation before starting disease-specific treatments.
KeywordsAutoimmune hepatitis Acute onset Intravenous glycyrrhizin Disease severity
Stronger Neo-Minophagen C
We are indebted to all our colleagues at the liver units of our hospitals who cared for the patients described here. This study was supported in part by a Health Labour Sciences Research Grant from the Ministry of Health, Labor and Welfare of Japan as a project by the Intractable Hepato-Biliary Disease Study Group of Japan.
Conflicts of interest
- 9.Yamamoto S, Maekawa Y, Imamura M, et al. Treatment of hepatitis with antiallergic drug, Stronger Neo-Minophagen C. Clin Med Pediatr. 1958;13:73.Google Scholar
- 10.Suzuki H, Ohta T, Takino T, et al. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double-blind trial. Asian Med J. 1983;26:423–438.Google Scholar
- 11.Hino K, Miyakawa H, Kondo T, et al. Effects of glycyrrhizin therapy on liver histology in chronic aggressive hepatitis. In: Shikata T, Porcell RH, Uchida T, eds. Viral hepatitis C, D and E. Amsterdam: Excerpta Medica; 1987:295–303.Google Scholar
- 16.Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute onset autoimmune hepatitis. Liver Int. (Epub ahead of print). doi: 10.1111/j.1478-3231.2011.02524.x
- 18.Doll R, Hill ID, Hutton C, et al. Clinical trial of a triterpenoid liquorice compound in gastric and duodenal ulcer. Lancet II. 1962;793–796.Google Scholar
- 32.Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during peg-interferon-alfa 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. (Epub ahead of print). doi: 10.1016/j.dld.2011.02.014
- 33.Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute onset AIH. Hepatology. (Epub ahead of print). doi: 10.1002/hep.24331